Developing new methods for the treatment and detection of diabetic retinopathy.

At i-RNA, our vision is your vision.

Our Vision:

A better world when it is seen better by everyone.

globally live with diabetes, with 10+ million new cases anually.

Most patients with diabetes are affected by diabetic retinopathy.

97% of type 1 diabetic patients and 60% of type 2 diabetic patients have diabetic retinopathy.

leading cause of blindness in working age adults worldwide.

New peer-reviewed study on lncRNA-targeting eyedrop approach for potential diabetic retinopathy therapy

i-RNA Corporation Receives Dual Awards at EFFERVESCENCE 2025

i-RNA Corporation Kicks Off 2026 with Strategic Industry Engagements at OBIO® Investment Summit and ATTD 2026

i-RNA Corporation Partners with JLABS @ Toronto to Drive Innovation in Diabetic Retinopathy Therapy